UK markets open in 7 hours 32 minutes

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
480.00-30.00 (-5.88%)
At close: 05:08PM GMT

MaxCyte, Inc.

9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700

IndustryMedical Devices
Full-time employees84

Key executives

NameTitlePayExercisedYear born
Mr. Douglas Arthur DoerflerFounder, Pres, CEO & Exec. Director1.39MN/A1956
Mr. Ronald Evan Holtz CPA, Ph.D.Chief Financial Officer649.38kN/A1958
Dr. J. Stark Thompson Ph.D.Consultant84.71kN/A1942
Dr. Cenk SumenChief Scientific OfficerN/AN/A1973
Mr. Sean MenarguezDirector of Investor RelationsN/AN/AN/A
Mr. Maher MasoudExec. VP, Gen. Counsel & Sec.N/AN/A1975
Mr. Thomas Michael RossExec. VP of Global SalesN/AN/A1961
Dr. James Brady Ph.D.Sr. VP of Technical Applications & Customer SupportN/AN/AN/A
Dr. Sarah Haecker Meeks Ph.D.Sr. VP of Bus. Devel.N/AN/AN/A
Mr. James LovgrenSr. VP of Global MarketingN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Corporate governance

MaxCyte, Inc.’s ISS governance QualityScore as of 28 November 2022 is 8. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.